SCHEMBL19686915

SCHEMBL19686915

Cc1cc(C)n(-c2cc(N[C@H]3CCN(C)C3=O)cc(NC3CCC(F)(F)CC3)n2)n1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KCNN2 Q9H2S1 1/20 0.39
KCNN3 Q9UGI6 1/20 0.39
MAPK1 P28482 1/20 0.32
IDH1 O75874 3/20 0.32
ADORA2A P29274 5/20 0.31
ADORA1 P30542 4/20 0.31
KCNH2 Q12809 1/20 0.31
ROCK2 O75116 3/20 0.31
PDE10A Q9Y233 1/20 0.31
SLC34A1 Q06495 2/20 0.30
SYK P43405 1/20 0.30
SMN1; SMN2 Q16637 2/20 0.30
TSHR P16473 1/20 0.30
LMNA P02545 1/20 0.30
GAA P10253 1/20 0.30
ALOX15 P16050 1/20 0.30
L3MBTL1 Q9Y468 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19686914 1.00 KCNN2 (0.39) KCNN2KCNN3MAPK1IDH1ADORA2A
SCHEMBL19686912 1.00 KCNN2 (0.39) KCNN2KCNN3MAPK1IDH1ADORA2A
SCHEMBL19687212 0.86 KCNN2 (0.51) KCNN2KCNN3IDH1ADORA2AADORA1
SCHEMBL19686272 0.86 KCNN2 (0.51) KCNN2KCNN3IDH1ADORA2AADORA1
SCHEMBL19687382 0.86 KCNN2 (0.51) KCNN2KCNN3IDH1ADORA2AADORA1
SCHEMBL19687280 0.81 KCNN2 (0.43) KCNN2KCNN3IDH1ADORA2AADORA1
SCHEMBL19687388 0.81 KCNN2 (0.52) KCNN2KCNN3ADORA2AADORA1ALOX15
SCHEMBL19686284 0.79 KCNN2 (0.49) KCNN2KCNN3IDH1SMN1; SMN2TSHR
SCHEMBL19687529 0.79 KCNN2 (0.45) KCNN2KCNN3MAPK1IDH1ADORA2A
SCHEMBL31127030 0.79 KCNN2 (0.45) KCNN2KCNN3MAPK1IDH1ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10774064-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-09-15 US disclosed
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2019-07-18 US disclosed
WO-2017139697-A9 BACTERIA ENGINEERED TO TREAT DISEASES ASSOCIATED WITH HYPERAMMONEMIA SYNLOGIC, INC. (US) 2017-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10774064-B2 Potassium channel modulators KCNJ11, KCNJ2, KCNJ1 KCNN2 5/4885KCNN3 11/4885MAPK1 717/4885
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS KCNJ11, KCNJ2, KCNJ1 KCNN2 5/4885KCNN3 11/4885MAPK1 717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.